Renovare Therapeutics, Inc. Announces Company Launch and Collaboration with CU Boulder Awardee of up to $33.5 Million in ARPA-H Funding to Advance Osteoarthritis Regenerative TherapiesBOULDER, Colo., April 06, 2026 (GLOBE NEWSWIRE) -- Renovare Therapeutics, Inc., a privately-held biotechnology company pioneering regenerative therapeutics for osteoarthritis, today announced its formal launch from stealth mode and collaboration with University of Colorado (CU) Boulder, which was awarded a contract of up to $33.5 million in 2024 from the Advanced Research Projects Agency for Health (ARPA-H) and recently announced its advancement into the second phase of the award. The non-dilutive funding, delivered under ARPA-H’s Novel Innovations for Tissue Regeneration in Osteoarthritis (NITRO) program, will support the continued development of lead product candidates through IND-enabling and first-in-human Phase 1 safety studies. Renovare will collaborate with CU Boulder to advance these and other novel therapies towards commercialization.
